AU1311195A - A method of treating neurogenic inflammation - Google Patents

A method of treating neurogenic inflammation

Info

Publication number
AU1311195A
AU1311195A AU13111/95A AU1311195A AU1311195A AU 1311195 A AU1311195 A AU 1311195A AU 13111/95 A AU13111/95 A AU 13111/95A AU 1311195 A AU1311195 A AU 1311195A AU 1311195 A AU1311195 A AU 1311195A
Authority
AU
Australia
Prior art keywords
neurogenic inflammation
treating neurogenic
treating
inflammation
neurogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13111/95A
Inventor
Knud Erik Andersen
Uffe Bang Olsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU1311195A publication Critical patent/AU1311195A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU13111/95A 1994-01-04 1995-01-03 A method of treating neurogenic inflammation Abandoned AU1311195A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK2094 1994-01-04
DK0020/94 1994-01-04
PCT/DK1995/000003 WO1995018615A1 (en) 1994-01-04 1995-01-03 A method of treating neurogenic inflammation

Publications (1)

Publication Number Publication Date
AU1311195A true AU1311195A (en) 1995-08-01

Family

ID=8088844

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13111/95A Abandoned AU1311195A (en) 1994-01-04 1995-01-03 A method of treating neurogenic inflammation

Country Status (13)

Country Link
EP (1) EP0735872A1 (en)
JP (1) JPH09507849A (en)
CN (1) CN1142183A (en)
AU (1) AU1311195A (en)
BR (1) BR9506453A (en)
CA (1) CA2180239A1 (en)
CZ (1) CZ198396A3 (en)
FI (1) FI962750A (en)
HU (1) HUT76281A (en)
IL (1) IL112223A0 (en)
NO (1) NO962812L (en)
WO (1) WO1995018615A1 (en)
ZA (1) ZA9530B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1138397A (en) * 1995-12-15 1997-07-14 Novo Nordisk A/S Novel method
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2965639A (en) * 1960-12-20 New basically substituted azepine
FI864246A (en) * 1985-11-08 1987-05-09 Warner Lambert Co N-SUBSTITUERADE 3-PIPERIDIN- ELLER 3-PYRIDINKARBOXYLSYROR SAMT DERAS DERIVAT.
DK93791D0 (en) * 1991-05-17 1991-05-17 Novo Nordisk As NEW HETEROCYCLIC CARBOXYLIC ACIDS

Also Published As

Publication number Publication date
WO1995018615A1 (en) 1995-07-13
HUT76281A (en) 1997-07-28
FI962750A (en) 1996-09-04
BR9506453A (en) 1997-09-02
CA2180239A1 (en) 1995-07-13
FI962750A0 (en) 1996-07-04
CZ198396A3 (en) 1997-01-15
EP0735872A1 (en) 1996-10-09
IL112223A0 (en) 1995-03-30
HU9601826D0 (en) 1996-09-30
ZA9530B (en) 1996-07-04
NO962812L (en) 1996-09-04
JPH09507849A (en) 1997-08-12
NO962812D0 (en) 1996-07-03
CN1142183A (en) 1997-02-05

Similar Documents

Publication Publication Date Title
AU6966696A (en) Method for treating and preventing inflammation and atherosclerosis
AU6430794A (en) A method of treating endo-osteal materials
AU2584695A (en) A method of treating organic material
AUPN271295A0 (en) Method of treatment
AU1683395A (en) A method of treating glaucoma
AU2808997A (en) Method for treating inflammation
AU2679195A (en) A method of coating
AU4901896A (en) Method for treating multiple sclerosis
AU1020997A (en) Method of treating sepsis
AU4703896A (en) Method for treating multiple sclerosis
AU2799195A (en) A method of creating an effect
AU1984195A (en) Masking method
AU4124296A (en) Method and installation for treating a medium
AU1311195A (en) A method of treating neurogenic inflammation
AU4027097A (en) Method of treatment
AU7113996A (en) Methods of treating beta-amyloid-associated conditions
AU3779595A (en) Method of treating turf
AU7280696A (en) A method of treating filariae
AU1422997A (en) Novel compounds and methods for treating multiple sclerosis
AU3989995A (en) Method of treating membranes
AU3488295A (en) Method of treating malignant conditions
AU3400695A (en) Method of drying of sludge
AU6831196A (en) A method of treating timber
AUPO269896A0 (en) A method of treatment
AU1829695A (en) Method of treatment of talc